Sudhir Agrawal

Sudhir Agrawal

UNVERIFIED PROFILE

Are you Sudhir Agrawal?   Register this Author

Register author
Sudhir Agrawal

Sudhir Agrawal

Publications by authors named "Sudhir Agrawal"

Are you Sudhir Agrawal?   Register this Author

96Publications

1356Reads

9Profile Views

Integration of 3D printing with dosage forms: A new perspective for modern healthcare.

Biomed Pharmacother 2018 Nov 4;107:146-154. Epub 2018 Aug 4.

Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, India.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07533322183184
Publisher Site
http://dx.doi.org/10.1016/j.biopha.2018.07.167DOI Listing
November 2018

Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.

Int J Oncol 2018 Sep 27;53(3):1193-1203. Epub 2018 Jun 27.

Idera Pharmaceuticals, Inc., Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2018.4456DOI Listing
September 2018

Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis.

Atherosclerosis 2017 06 13;261:26-36. Epub 2017 Apr 13.

Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosis.2017.04.011DOI Listing
June 2017

Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494.

Mol Ther Nucleic Acids 2017 Jun 14;7:61-70. Epub 2017 Mar 14.

Department of Surgery, Leiden University Medical Center, 2333 Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2333 Leiden, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.omtn.2017.03.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415962PMC
June 2017

RAGE Enhances TLR Responses through Binding and Internalization of RNA.

J Immunol 2016 11 19;197(10):4118-4126. Epub 2016 Oct 19.

Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1502169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062438PMC
November 2016

Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms.

J Immunol 2014 Oct 3;193(7):3257-61. Epub 2014 Sep 3.

Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany; Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655; and German Center for Neurodegenerative Diseases, 53175 Bonn, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1301886DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170058PMC
October 2014

A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice.

Autoimmunity 2013 Nov 12;46(7):419-28. Epub 2013 Jun 12.

Idera Pharmaceuticals, Inc. , Cambridge, Massachusetts , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08916934.2013.798651DOI Listing
November 2013

Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.

Nucleic Acids Res 2013 Apr 8;41(6):3947-61. Epub 2013 Feb 8.

Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkt078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616729PMC
April 2013

Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.

ACS Med Chem Lett 2013 Feb 29;4(2):302-5. Epub 2013 Jan 29.

Idera Pharmaceuticals, Inc. , 167 Sidney Street, Cambridge, Massachusetts 02139, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ml300482zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027476PMC
February 2013

An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy.

PLoS One 2012 30;7(5):e38111. Epub 2012 May 30.

Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038111PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364192PMC
October 2012

TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome.

PLoS One 2012 4;7(1):e29357. Epub 2012 Jan 4.

Department of Radiation Oncology, Albert Einstein College of Medicine, The Montefiore Medical Center, Bronx, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0029357PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251576PMC
May 2012

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.

Clin Cancer Res 2011 Oct 2;17(20):6531-41. Epub 2011 Sep 2.

Dipartmento di Endocrinologia ed Oncologia Molecolare e Clinica, Università di Napoli Federico II, Naples, Italy.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-10-3376DOI Listing
October 2011

PKA knockdown enhances cell killing in response to radiation and androgen deprivation.

Int J Cancer 2011 Feb 19;128(4):962-73. Epub 2010 Oct 19.

Basic Science Division, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.25634DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391603PMC
February 2011

Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.

Mol Cancer Ther 2010 Jun 1;9(6):1788-97. Epub 2010 Jun 1.

Idera Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-09-1198DOI Listing
June 2010

Remembering Paul C. Zamecnik, M.D., "father of antisense" (1912-2009).

Authors:
Sudhir Agrawal

Oligonucleotides 2010 Feb;20(1):47-50

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/oli.2009.2001.obzDOI Listing
February 2010

Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.

J Med Chem 2009 Nov;52(21):6871-9

Idera Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm901145sDOI Listing
November 2009

A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.

Clin Cancer Res 2009 Nov 10;15(22):6921-30. Epub 2009 Nov 10.

Departments of Endocrinologia ed Oncologia Molecolare e Clinica, and Biologia e Patologia Cellulare e Molecolare L. Califano, Università di Napoli Federico II, Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1599DOI Listing
November 2009

Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8.

Biochem Biophys Res Commun 2009 Aug 11;386(3):443-8. Epub 2009 Jun 11.

Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2009.06.036DOI Listing
August 2009

Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8.

Bioorg Med Chem Lett 2009 Apr 10;19(7):2044-7. Epub 2009 Feb 10.

Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, MA 02139, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.02.021DOI Listing
April 2009

Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.

J Med Chem 2009 Jan;52(2):551-8

Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm8014316DOI Listing
January 2009

Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.

Antimicrob Agents Chemother 2008 Dec 13;52(12):4320-5. Epub 2008 Oct 13.

Idera Pharmaceuticals, 167 Sidney Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.00701-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592873PMC
December 2008

Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.

J Med Chem 2007 Dec 8;50(25):6411-8. Epub 2007 Nov 8.

Idera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm070881lDOI Listing
December 2007

Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice.

J Allergy Clin Immunol 2007 Sep 20;120(3):631-7. Epub 2007 Jun 20.

Idera Pharmaceuticals, Inc, Cambridge, Mass, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2007.05.015DOI Listing
September 2007

Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in rats.

Otolaryngol Head Neck Surg 2007 Aug;137(2):250-5

Department of Otolaryngology-Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1016/j.otohns.2007.03.004
Publisher Site
http://dx.doi.org/10.1016/j.otohns.2007.03.004DOI Listing
August 2007

Immune modulatory oligonucleotides in the prevention and treatment of OVA-induced eustachian tube dysfunction in rats.

Otolaryngol Head Neck Surg 2007 Aug;137(2):321-6

Department of Otolaryngology--Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.otohns.2007.02.016DOI Listing
August 2007

Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.

Int J Radiat Oncol Biol Phys 2007 Jul;68(4):1151-60

Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2007.03.047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763094PMC
July 2007

The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunction.

Int J Pediatr Otorhinolaryngol 2006 Dec 30;70(12):2019-26. Epub 2006 Aug 30.

Department of Otolaryngology-Head and Neck Surgery, CB# 7070, G0412 Neurosciences Hospital, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7070, United States.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016558760600238
Publisher Site
http://dx.doi.org/10.1016/j.ijporl.2006.07.016DOI Listing
December 2006

Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy.

Mol Cancer Ther 2006 Aug;5(8):2106-14

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Boulevard, 113 Volker Hall, 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0158DOI Listing
August 2006

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.

Mol Cancer Ther 2006 Jun;5(6):1585-92

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294-0019, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0094DOI Listing
June 2006

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

Clin Cancer Res 2006 Jan;12(2):577-83

Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Istituto di Anatomia Patologica, and Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli Federico II, Via S. Pansini 5, 80131 Naples, Italy.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-05-1943DOI Listing
January 2006

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.

Oncogene 2005 Nov;24(48):7238-47

Department of Pharmacology and Toxicology and Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1208814
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1208814DOI Listing
November 2005

Novel MDM2 p53-independent functions identified through RNA silencing technologies.

Ann N Y Acad Sci 2005 Nov;1058:205-14

Department of Pharmacology and Toxicology and Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1359.030DOI Listing
November 2005

Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.

Int Immunopharmacol 2005 Jun;5(6):981-91

Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02139-4818, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2005.01.002DOI Listing
June 2005

Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.

Curr Cancer Drug Targets 2005 Feb;5(1):43-9

Departments of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009053332663DOI Listing
February 2005

Role of Toll-like receptors in antisense and siRNA [corrected].

Nat Biotechnol 2004 Dec;22(12):1533-7

Hybridon, Inc., 345 Vassar Street, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt1042DOI Listing
December 2004

CRIPTO-1: a novel target for therapeutic intervention in human carcinoma.

Int J Oncol 2004 Oct;25(4):1013-20

Department of Experimental Oncology, INT-Fondazione Pascale, Via Mariano Semmola, I-80131 Naples, Italy.

View Article

Download full-text PDF

Source
October 2004

Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics.

Oncogene 2004 Oct;23(49):8105-17

Aegera Oncology Inc., University of Ottawa and Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada K1H 8L1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1207967DOI Listing
October 2004

Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.

Prostate 2004 Aug;60(3):187-96

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pros.20044
Publisher Site
http://dx.doi.org/10.1002/pros.20044DOI Listing
August 2004

Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice.

Int Immunopharmacol 2004 Jul;4(7):851-62

Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2004.03.009DOI Listing
July 2004

Impact of site-specific nucleobase deletions on the arthritogenicity of DNA.

Inflammation 2004 Jun;28(3):159-68

Department of Rheumatology and Inflammation Research, University of Göteborg, Göteborg, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/b:ifla.0000039562.30451.0aDOI Listing
June 2004

Hybridization-based fluorescence assay allows quantitation of single-stranded oligodeoxynucleotides in low nanomolar range.

Anal Biochem 2004 May;328(1):93-5

Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2004.01.005DOI Listing
May 2004

Induction of immune activation by a novel immunomodulatory oligonucleotide without thymocyte apoptosis.

Biochem Biophys Res Commun 2004 May;318(1):60-6

Division of Rheumatology and Department of Immunology, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2004.04.001DOI Listing
May 2004

MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.

J Biol Chem 2004 Apr 3;279(16):16000-6. Epub 2004 Feb 3.

Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M312264200DOI Listing
April 2004

Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.

Int J Radiat Oncol Biol Phys 2004 Feb;58(2):336-43

Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2003.09.029DOI Listing
February 2004

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.

Clin Cancer Res 2004 Feb;10(4):1263-73

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.ccr-0245-03DOI Listing
February 2004

Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma.

Int Immunopharmacol 2004 Jan;4(1):127-38

Medical Microbiology and Immunology and Biomedical Sciences, Center for Allergy, Asthma and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S156757690300284
Publisher Site
http://dx.doi.org/10.1016/j.intimp.2003.11.005DOI Listing
January 2004

Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA.

Ann N Y Acad Sci 2003 Dec;1002:30-42

Hybridon, Inc., Cambridge, Massuchusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1281.005DOI Listing
December 2003

Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.

Ann N Y Acad Sci 2003 Dec;1002:217-35

Departments of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, Alabama 35294-0019, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1281.025DOI Listing
December 2003

Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells.

Biochem Biophys Res Commun 2003 Oct;310(4):1133-9

Hybridon, Inc., 345 Vassar Street,Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2003.09.134DOI Listing
October 2003

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.

Proc Natl Acad Sci U S A 2003 Sep 16;100(20):11636-41. Epub 2003 Sep 16.

Department of Pharmacology and Toxicology and Comprehensive Cancer Center, University of Alabama at Birmingham, VH 113, 1670 University Boulevard, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1934692100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC208810PMC
September 2003

Was induction of HIV-1 through TLR9?

J Immunol 2003 Aug;171(4):1621; author reply 1621-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.171.4.1621DOI Listing
August 2003

Secondary structures in CpG oligonucleotides affect immunostimulatory activity.

Biochem Biophys Res Commun 2003 Jul;306(4):948-53

Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139-4818, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(03)01080-5DOI Listing
July 2003

Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity.

Bioconjug Chem 2002 Sep-Oct;13(5):966-74

Hybridon, Inc., 345 Vassar Street, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc0200374DOI Listing
June 2003

Chemistry of CpG DNA.

Curr Protoc Nucleic Acid Chem 2003 May;Chapter 4:Unit 4.16

Hybridon, Inc., Cambridge, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/0471142700.nc0416s12DOI Listing
May 2003

Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA.

Bioorg Med Chem 2003 Feb;11(3):459-64

Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0968-0896(02)00430-3DOI Listing
February 2003

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.

Prostate 2003 Feb;54(3):194-205

Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.10187DOI Listing
February 2003

CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents.

Biochem Biophys Res Commun 2003 Jan;300(4):853-61

Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(02)02943-1DOI Listing
January 2003

Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties.

Biochem Biophys Res Commun 2002 Sep;297(1):83-90

Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(02)02127-7DOI Listing
September 2002

Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.

Anticancer Res 2002 Jan-Feb;22(1A):107-16

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 35294-0019, USA.

View Article

Download full-text PDF

Source
June 2002

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

Int J Oncol 2002 Apr;20(4):745-52

Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
April 2002

Towards optimal design of second-generation immunomodulatory oligonucleotides.

Curr Opin Mol Ther 2002 Apr;4(2):122-9

Hybridon Inc., Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
April 2002

Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

Mol Med 2002 Apr;8(4):185-99

Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2039984PMC
April 2002

Medicinal chemistry and therapeutic potential of CpG DNA.

Trends Mol Med 2002 Mar;8(3):114-21

Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02137, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1471-4914(01)02264-xDOI Listing
March 2002

Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.

Clin Cancer Res 2002 Feb;8(2):607-14

Cellular Biochemistry Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute/NIH, Bethesda, MD 20892-1750, USA.

View Article

Download full-text PDF

Source
February 2002

Thermal stress-induced HSP70 mediates protection against intrapancreatic trypsinogen activation and acute pancreatitis in rats.

Gastroenterology 2002 Jan;122(1):156-65

Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/gast.2002.30314DOI Listing
January 2002